Evolution of the inflammatory profile and redox status in COVID-19 patients: Possible therapeutic targets?

  • Funded by National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)
  • Total publications:0 publications

Grant number: COV20_00491

Grant search

Key facts

  • Disease

    COVID-19
  • Funder

    National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)
  • Principal Investigator

    Eduardo Tamayo Gómez
  • Research Location

    Spain
  • Lead Research Institution

    Hospital Clínico Universitario de Valladolid
  • Research Priority Alignment

    N/A
  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Prognostic factors for disease severity

  • Special Interest Tags

    Innovation

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The risk of patients with COVID19 increases with age, as does the redox status and the inflammatory component. In relation to the hypothesis of this work is that in COVID19 patients there is an inflammatory profile associated with the severity of the disease that evolves depending on the ability of the patient to stabilize its redox status. The objectives of this work are to carry out a clinical biological and molecular characterization of the Covid19 disease as well as to establish one of innovative therapeutic targets and prognostic biomarkers of clinical activity and even death that can considerably reduce the mortality trend that our country currently suffers.